Compare CRDL & INVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | INVZ |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | Canada | Israel |
| Employees | N/A | 372 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.6M | 129.5M |
| IPO Year | 2017 | N/A |
| Metric | CRDL | INVZ |
|---|---|---|
| Price | $1.18 | $0.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.50 | $2.68 |
| AVG Volume (30 Days) | 806.5K | ★ 2.0M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.61 |
| Revenue Next Year | N/A | $53.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.54 |
| 52 Week High | $1.71 | $2.54 |
| Indicator | CRDL | INVZ |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 31.22 |
| Support Level | $0.95 | N/A |
| Resistance Level | $1.38 | $0.72 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 60.13 | 14.04 |
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Innoviz Technologies Ltd is a provider of LiDAR technology, serving as a Tier 1 supplier to the world's automotive manufacturers. Its LiDAR and perception software "see" further than a human driver and reduce the possibility of error, meeting the automotive industry's strictest expectations for performance and safety. Its sensors are designed to deliver exceptional range, resolution, and reliability, providing accurate 3D sensing in harsh weather conditions. Operating across the U.S., Europe, and Asia. Innoviz designs solutions for automotive OEMs, system integrators, municipalities, commercial enterprises, and others. InnovizSMART is an off-the-shelf solution for security, defense, and homeland security, intelligent traffic management, mobility, robotics, and aerial applications.